References
- Pérez-González A, Araújo-Ameijeiras A, Fernández-Villar A, et al. Long COVID in hospitalized and non-hospitalized patients in a large cohort in Northwest Spain, a prospective cohort study. Sci Rep. 2022;12(1):3369. doi: 10.1038/s41598-022-07414-x
- Bohmwald K, Gálvez NMS, Canedo-Marroquín G, et al. Contribution of cytokines to tissue damage during human respiratory syncytial virus infection. Front Immunol. 2019;10:452. doi: 10.3389/fimmu.2019.00452
- Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nat Rev Microbiol. 2019;17(4):233–245. doi: 10.1038/s41579-019-0149-x
- Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention. J Pediatr Pharmacol Ther. 2009;14(2):75–85. doi: 10.5863/1551-6776-14.2.75
- Hall CB, Douglas RG Jr., Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis. 1980;141(1):98–102. doi: 10.1093/infdis/141.1.98
- Kutter JS, Spronken MI, Fraaij PL, et al. Transmission routes of respiratory viruses among humans. Curr Opin Virol. 2018;28:142–151. doi: 10.1016/j.coviro.2018.01.001
- Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV). 2024 Jan 4. Available from: https://www.cdc.gov/rsv/index.html
- Munywoki PK, Koech DC, Agoti CN, et al. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Infect. 2015;143(4):804–812. doi: 10.1017/S0950268814001393
- Kaler J, Hussain A, Patel K, et al. Respiratory syncytial virus: a comprehensive review of transmission, pathophysiology, and manifestation. Cureus. 2023;15(3):e36342. doi: 10.7759/cureus.36342
- Center for Disease Control and Prevention. RSV in Infants and Young Children. 2023 Oct. Available from: https://www.cdc.gov/rsv/high-risk/infants-young-children.html
- Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047–2064. doi: 10.1016/S0140-6736(22)00478-0
- Munro APS, Martinón-Torres F, Drysdale SB, et al. The disease burden of respiratory syncytial virus in infants. Curr Opin Infect Dis. 2023;36(5):379–384. doi: 10.1097/QCO.0000000000000952
- Drysdale SB, Cathie K, Flamein F, et al. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425–2435. doi: 10.1056/NEJMoa2309189
- Hamilton MA, Liu Y, Calzavara A, et al. Predictors of all-cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS-CoV-2. Influenza Other Respir Viruses. 2022;16(6):1072–1081. doi: 10.1111/irv.13004
- Holman HR. The relation of the chronic disease epidemic to the health care crisis. ACR Open Rheumatol. 2020;2(3):167–173. doi: 10.1002/acr2.11114
- Centers for Disease Control and Prevention. Health and economic costs of chronic diseases. 2023 Mar 23. Available from: https://www.cdc.gov/chronicdisease/about/costs/index.htm
- Public Health Agency of Canada. Aging and chronic diseases: a profile of Canadian seniors. 2020 Dec. Available from: https://www.canada.ca/content/dam/hc-sc/documents/services/publications/diseases-and-conditions/aging-chronic-diseases/canadian-seniors-report_2021-eng.pdf
- Nguyen-Van-Tam JS, O’Leary M, Martin ET, et al. Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries. Eur Respir Rev. 2022;31(166):220105. doi: 10.1183/16000617.0105-2022
- Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. doi: 10.7189/jogh.09.020421
- Hansen CL, Chaves SS, Demont C, et al. Mortality associated with influenza and respiratory syncytial virus in the US, 1999-2018. JAMA Netw Open. 2022;5(2):e220527. doi: 10.1001/jamanetworkopen.2022.0527
- Juhn YJ, Wi CI, Takahashi PY, et al. Incidence of respiratory syncytial virus infection in older adults before and during the COVID-19 pandemic. JAMA Netw Open. 2023;6(1):e2250634. doi: 10.1001/jamanetworkopen.2022.50634
- Falsey AR, Walsh EE, Osborne RH, et al. Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by respiratory intensity and impact questionnaire. Influenza Other Respir Viruses. 2022;16(1):79–89. doi: 10.1111/irv.12903
- Kampmann B, Madhi SA, Munjal I, et al. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023;388(16):1451–1464. doi: 10.1056/NEJMoa2216480
- Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608. doi: 10.1056/NEJMoa2209604
- Feldman RG, Antonelli-Incalzi R, Steenackers K, et al. Respiratory syncytial virus prefusion F protein vaccine is efficacious in older adults with underlying medical conditions. Clin Infect Dis. 2023;72(Supplement_1). doi: 10.2337/db23-280-LB
- Ripa M, Mastrangelo A. The elephant in the room: secondary infections and antimicrobial use in patients with COVID-19. Chest. 2021;160(2):387–388. doi: 10.1016/j.chest.2021.04.053
- Grasselli G, Scaravilli V, Mangioni D, et al. Hospital-acquired infections in critically Ill patients with COVID-19. Chest. 2021;160(2):454–465. doi: 10.1016/j.chest.2021.04.002
- School of Public Health. Exploring the cost-effectiveness of RSV vaccines in older adults. 2023. Available from: https://sph.umich.edu/news/2023posts/exploring-the-cost-effectiveness-of-rsv-vaccines-in-older-adults.html#:~:text=Our%20best%20estimate%20is%20that,Quality%2DAdjusted%20Life%20Year
- Wang Y, Fekadu G, You JHS. Comparative cost-effectiveness analysis of respiratory syncytial virus vaccines for older adults in Hong Kong. Vaccines. 2023;11(10):1605. doi: 10.3390/vaccines11101605
- Tuite AR, Ng V, Ximenes R, et al. Quantifying th economic gains associated with COVID-19 vaccination. June. 2023;49(6):263–273. Available from: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2023-49/issue-6-june-2023/quantifying-economic-gains-associated-covid-19-vaccination.html
- Utami AM, Rendrayani F, Khoiry QA, et al. Economic evaluation of COVID-19 vaccination: a systematic review. J Glob Health. 2023;13:06001. doi: 10.7189/jogh.13.06001
- Connolly L Can adults get RSV? 2022 Nov 9. Available from: https://health.ucdavis.edu/news/headlines/can-adults-get-rsv/2022/11#:~:text=Can%20RSV%20infections%20can%20be,this%20case%2C%2065%20and%20older
- Ramirez JA, Musher DM, Evans SE, et al. Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest. 2020;158(5):1896–1911. doi: 10.1016/j.chest.2020.05.598
- Rosas-Salazar C, Chirkova T, Gebretsadik T, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study. Lancet. 2023;401(10389):1669–1680. doi: 10.1016/S0140-6736(23)00811-5
- Chirkova T, Rosas-Salazar C, Gebretsadik T, et al. Effect of infant RSV infection on memory T cell responses at age 2-3 years. Front Immunol. 2022;13:826666. doi: 10.3389/fimmu.2022.826666